Daiichi chief 'confident' in Ranbaxy's future

The head of Daiichi Sankyo, the Japanese pharmaceutical company, expressed his regrets over the high cost of the purchase last year of Ranbaxy, the Indian generic drugs group, while defending the future benefits of the deal. Report

Suggested Articles

Imbruvica has enjoyed a nice run in previously untreated CLL over the last few years. But major competition is here in the form of AZ's Calquence.

Pennsylvania's Supreme Court revived thousands of lawsuits alleging the antipsychotic med Risperdal caused males to develop breasts.

In the asthma biologics race, there doesn't appear to be a clear favorite among Xolair, Dupixent, Fasenra and Nucala for a group of pulmonologists.